GURUFOCUS.COM » STOCK LIST » Financial Services » Insurance » Hubei Biocause Pharmaceutical Co Ltd (SZSE:000627) » Definitions » Revenue

Hubei Biocause Pharmaceutical Co (SZSE:000627) Revenue : ¥45,258 Mil (TTM As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Hubei Biocause Pharmaceutical Co Revenue?

Hubei Biocause Pharmaceutical Co's revenue for the three months ended in Mar. 2024 was ¥17,487 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ¥45,258 Mil. Hubei Biocause Pharmaceutical Co's Revenue per Share for the three months ended in Mar. 2024 was ¥3.54. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ¥8.89.

Warning Sign:

Hubei Biocause Pharmaceutical Co Ltd revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Hubei Biocause Pharmaceutical Co was -27.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 5.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 7.90% per year. During the past 10 years, the average Revenue per Share Growth Rate was 36.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Hubei Biocause Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 175.60% per year. The lowest was -11.60% per year. And the median was 9.75% per year.


Hubei Biocause Pharmaceutical Co Revenue Historical Data

The historical data trend for Hubei Biocause Pharmaceutical Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hubei Biocause Pharmaceutical Co Revenue Chart

Hubei Biocause Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50,192.08 41,200.41 49,583.19 49,615.70 49,698.87

Hubei Biocause Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21,927.56 11,504.75 7,755.70 8,510.86 17,487.01

Competitive Comparison of Hubei Biocause Pharmaceutical Co's Revenue

For the Insurance - Life subindustry, Hubei Biocause Pharmaceutical Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hubei Biocause Pharmaceutical Co's Revenue Distribution in the Insurance Industry

For the Insurance industry and Financial Services sector, Hubei Biocause Pharmaceutical Co's Revenue distribution charts can be found below:

* The bar in red indicates where Hubei Biocause Pharmaceutical Co's Revenue falls into.



Hubei Biocause Pharmaceutical Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥45,258 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hubei Biocause Pharmaceutical Co  (SZSE:000627) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Hubei Biocause Pharmaceutical Co Revenue Related Terms

Thank you for viewing the detailed overview of Hubei Biocause Pharmaceutical Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hubei Biocause Pharmaceutical Co (SZSE:000627) Business Description

Traded in Other Exchanges
N/A
Address
2nd Floor, Building 1, No. 1 Tianshan Road, Guohua Huijin Center, Zhanghe New District, Hubei Province, Jingmen, CHN, 448000
Hubei Biocause Pharmaceutical Co Ltd is a China-based company engaged in life insurance, health insurance, accident insurance, and other life insurance businesses, medicine, and chemical businesses. The company generates its revenue in the form of premiums.

Hubei Biocause Pharmaceutical Co (SZSE:000627) Headlines

No Headlines